Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

Trial Profile

Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs Axalimogene filolisbac (Primary)
  • Indications Cervical cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AIM2CERV
  • Sponsors Advaxis
  • Most Recent Events

    • 02 Mar 2017 According to an Advaxis media release, update on this trial will be presented at Society of Gynecologic Oncology (SGO) Annual Meeting.
    • 06 Feb 2017 According to an Advaxis media release, the first patient has been enrolled and dosed in this trial.
    • 11 Oct 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top